Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with an investment in MinervaX
Mandate

Vinge advises Industrifonden in connection with an investment in MinervaX

December 16, 2020 Employment and Benefits Intellectual Property M&A

Vinge has advised Industrifonden in connection with its investment in MinervaX.

MinervaX has developed a vaccine against streptococcus and in connection with the financing round has procured a total of MEUR 47.4 from a syndicate consisting of Industrifonden, Sanofi Ventures, Wellington Partners and Adjuvant Capital.

Vinge’s team primarily consisted of Johan Larsson, Sara Strandberg and Stojan Arnerstål.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

 Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

 Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025